Posts by Alison Baldyga

Oncology R&D Outlook 2020: The Ongoing Impact of COVID-19

Oncology and Alzheimer's

By Dennis Chang, Dan Holohan, Edouard Mullarky, and Rachit Neupane COVID-19 has escalated into a global pandemic with shocking speed and poses an unprecedented challenge for all facets of society. Oncology research and development has been no exception. Necessary measures to slow the spread of the disease (e.g. travel restrictions, quarantines, and social distancing), or…

Read More

2019 Oncology Outlook

Oncology and Alzheimer's

Oncology drug development continues at an unprecedented pace—our experts examine recent trends and detail what to expect this year: The first immunotherapy + targeted therapy combinations on the verge of launch Immune checkpoint inhibitors have received over 40 FDA approvals already, but thus far all approvals have been for IO monotherapy or for IO+IO or…

Read More

2018 Oncology Year in Review: New Cancer Drug Approvals

Cancer drug approvals

In 2018, the biopharma industry made groundbreaking advances in oncology with 44 drug approvals in the US. “The pace of progress in cancer treatment is extraordinary and is the result of our industry and research community pushing forward on all fronts,” observes Dennis Chang, principal at Clarion. Below we highlight several of these approvals, encompassing…

Read More

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.